Vocci F, Chiang C N, Cummings L, Hawks R
Medications Development Division, National Institute on Drug Abuse, Rockville, MD 20857, USA.
NIDA Res Monogr. 1995;149:4-15.
Drug abuse is of great public concern, and effective treatment strategies for opiate and cocaine dependence are urgently needed for the general addict population as well as for pregnant women and their infants. NIDA's effort to develop new pharmacotherapies as an adjunct to the treatment of opiate addiction has already led to the approval of LAAM and an NDA development program for buprenorphine. The momentum achieved by the new Medications Development Program's success with opiate addiction treatment must now be applied to the development of new treatments for cocaine addiction. With recent advances in neuroscience, imaging techniques, and pharmaceutical technology, the development of medications for significantly improving drug abuse treatment in a variety of directions holds real promise.
药物滥用是一个备受公众关注的问题，对于普通成瘾人群以及孕妇及其婴儿而言，迫切需要针对阿片类药物和可卡因依赖的有效治疗策略。美国国家药物滥用研究所（NIDA）致力于开发新的药物疗法作为阿片类药物成瘾治疗的辅助手段，这已经促使LAAM获得批准，并启动了丁丙诺啡的新药申请（NDA）开发项目。新药物开发项目在阿片类药物成瘾治疗方面取得成功所带来的发展势头，现在必须应用于可卡因成瘾新治疗方法的开发。随着神经科学、成像技术和制药技术的最新进展，朝着多个方向开发能够显著改善药物滥用治疗的药物具有切实的前景。
